Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Approvals/NMPA/Alprostadil for Injection

Approved

化学药品

Alprostadil for Injection

UCB Pharma GmbH🇨🇳 National Medical Products Administration

Approval Date: Jan 24, 2018
Approval ID: 7MazXbVXwOX
Company: UCB Pharma GmbH
Type: 化学药品

Approval Details

Approval Id: 7MazXbVXwOX
Approval Number: H20181056
Generic Name: 注射用前列地尔
Generic Name En: Alprostadil for Injection
Trade Name: 保达新
Drug Type: 化学药品
Dosage Form: 注射剂
Strength: 20μg
Reg Date: 2018-01-24
Expired Date: 2023-01-23
Company Name: UCB Pharma GmbH
Company Address: Alfred-Nobel-Str.10,40789 Monheim,Germany
Production Company Name: Bayer Pharma AG
Production Company Address: Kaiser-Wilhelm-Allee 51368 Leverkusen,Germany
Company Detail Path: /organization/ucb-pharma-gmbh
Production Company Detail Path: /organization/bayer-pharma-ag

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Jan 24, 2018

Approval ID

7MazXbVXwOX

Type

化学药品

Back to NMPA Approvals

保达新 - NMPA Drug Approval Details